Sugi Predict

Sugi Predict / Compounds / SCHEMBL14975606

SCHEMBL14975606

SCHEMBL14975606

CCCCc1ccccc1C(=O)OC(CCCC)COC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ ALDH1A1 P00352 6/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CA2 P00918 1/20 0.45
▸ TSHR P16473 4/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ LMNA P02545 3/20 0.42
▸ TP53 P04637 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ PRKCA P17252 1/20 0.40
▸ PRKCD Q05655 1/20 0.40
▸ PRSS1 P07477 1/20 0.40
▸ PRSS2 P07478 1/20 0.40
▸ PRSS3 P35030 1/20 0.40
▸ SCN1A P35498 2/20 0.39
▸ SCN2A Q99250 2/20 0.39
▸ SCN3A Q9NY46 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14975376 0.96 ALDH1A1 (0.47) KMT2AMEN1ALDH1A1CYP3A4CA2
SCHEMBL14975596 0.95 ALDH1A1 (0.49) KMT2AMEN1ALDH1A1CYP3A4CA2
SCHEMBL14975109 0.95 ALDH1A1 (0.49) KMT2AMEN1ALDH1A1CYP3A4CA2
SCHEMBL14974985 0.95 ALDH1A1 (0.49) KMT2AMEN1ALDH1A1CYP3A4CA2
SCHEMBL14974593 0.95 ALDH1A1 (0.49) KMT2AMEN1ALDH1A1CYP3A4CA2
SCHEMBL14975234 0.95 KMT2A (0.46) KMT2AMEN1ALDH1A1CYP3A4CA2
SCHEMBL14974870 0.95 KMT2A (0.46) KMT2AMEN1ALDH1A1CYP3A4CA2
SCHEMBL14974446 0.93 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1CYP3A4CA2
SCHEMBL14975126 0.93 KMT2A (0.44) KMT2AMEN1ALDH1A1CYP3A4CA2
SCHEMBL14974760 0.92 KMT2A (0.48) KMT2AMEN1ALDH1A1CYP3A4CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2785752-B1 INTERNAL ELECTRON DONOR FOR OLEFIN POLYMERIZATION CATALYSTS, METHOD OF MAKING AND USING THE SAME BRASKEM AMERICA INC (US) 2023-05-31 — — EP claimed
EP-2785752-A1 INTERNAL ELECTRON DONOR FOR OLEFIN POLYMERIZATION CATALYSTS, METHOD OF MAKING AND USING THE SAME BASF Corporation (US) 2014-10-08 — — EP claimed
WO-2013082631-A1 INTERNAL ELECTRON DONOR FOR OLEFIN POLYMERIZATION CATALYSTS, METHOD OF MAKING AND USING THE SAME BASF CORPORATION (US) 2013-06-06 — — WO claimed
US-10954251-B2 Thienopyrimidine inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-03-23 — — US disclosed
US-20190106433-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C WINDTREE THERAPEUTICS, INC. 2019-04-11 — — US disclosed
US-10183950-B2 Thienopyrimidine inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-01-22 — — US disclosed
US-20170158706-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-06-08 — — US disclosed
US-9604994-B2 Thienopyrimidine inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-03-28 — — US disclosed
EP-3048106-A1 THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C Cancer Research Technology Limited (GB) 2016-07-27 — — EP disclosed
EP-2782917-B1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER REC TECH LTD (GB) 2016-03-02 — — EP disclosed
US-20140323435-A1 Thienopyrimidine Inhibitors of Atypical Protein Kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-10-30 — — US disclosed
EP-2785752-A1 INTERNAL ELECTRON DONOR FOR OLEFIN POLYMERIZATION CATALYSTS, METHOD OF MAKING AND USING THE SAME BASF Corporation (US) 2014-10-08 — — EP disclosed
EP-2782917-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C Cancer Research Technology Limited (GB) 2014-10-01 — — EP disclosed
WO-2013082631-A1 INTERNAL ELECTRON DONOR FOR OLEFIN POLYMERIZATION CATALYSTS, METHOD OF MAKING AND USING THE SAME BASF CORPORATION (US) 2013-06-06 — — WO disclosed
WO-2013078126-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10183950-B2 Thienopyrimidine inhibitors of atypical protein kinase C PRKCQ, PRKDC, PRKACA KMT2A 1606/4885MEN1 3597/4885ALDH1A1 3832/4885
US-20190106433-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C PRKX, PRKCQ, PRKACA KMT2A 1428/4885MEN1 3225/4885ALDH1A1 4002/4885
US-10954251-B2 Thienopyrimidine inhibitors of atypical protein kinase C PRKX, PRKCQ, PRKACA KMT2A 1428/4885MEN1 3225/4885ALDH1A1 4002/4885
US-20140323435-A1 Thienopyrimidine Inhibitors of Atypical Protein Kinase C PRKCQ, PRKDC, PRKACA KMT2A 1606/4885MEN1 3597/4885ALDH1A1 3832/4885
US-20170158706-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C PRKCQ, PRKDC, PRKACA KMT2A 1606/4885MEN1 3597/4885ALDH1A1 3832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.